Why this Houston medical device innovator is pumped up for the first total artificial heart

HOUSTON INNOVATORS PODCAST EPISODE 248

Dr. William Cohn is the chief medical officer for BiVACOR, a medical device company creating the first total artificial heart. Photo via TMC

It's hard to understate the impact Dr. William Cohn has had on cardiovascular health as a surgeon at the Texas Heart Institute or on health care innovation as the director of the Center for Device Innovation at the Texas Medical Center. However, his role as chief medical officer of BiVACOR might be his most significant contribution to health care yet.

The company's Total Artificial Heart is unlike any cardiovascular device that's existed, Cohn explains on the Houston Innovators Podcast. While most devices are used temporarily for patients awaiting a heart transplant, BiVACOR's TAH has the potential to be a permanent solution for the 200,000 patients who die of heart failure annually. Last year, only around 4,000 patients were able to receive heart transplants.

"Artificial hearts historically have had bladders that ejected and filled 144,000 times a day. They work great for temporary support, but no one is suggesting they are permanent devices," Cohn says on the show.

The difference with BiVACOR's device is it abandons the bladder approach. Cohn explains that as assist pumps evolved — something his colleague, Dr. Bud Frasier, had a huge impact on — they featured new turbine and rotor technology. Daniel Timms, BiVACOR's founder and CTO, iterated on this technology beginning when he was a postdoctoral student at Queensland University of Technology in Australia.

"BiVACOR is the first artificial heart that leverages what we learned from that whole period — it has no bladders, it has no valves. It has one moving part, and that moving part is suspended in an electromagnetic field controlled by a computer and changed thousands of times a second," Cohn says. "It will never wear out, and that's why we think it's the world's first total artificial heart."

The company is seeing momentum, celebrating its first successful human implantation last month. The device was used for eight days on a patient at Baylor St. Luke’s Medical Center before the patient received a heart transplant.

Cohn says that BiVACOR has plans to use the TAH as "bridge-to-transplant" device in several other surgeries and expects to get FDA approval for that purpose in the next three to four years before working toward clearance for total artificial heart transplants.

Cohn has worked to support medical device startups at CDI at TMC for the seven years it has existed — first under Johnson and Johnson and then under TMC when it took the program over. He describes the center and its location as the ideal place for developing the future of health care, with Houston rising up to compete with regions known for medical device success — both coasts and Minnesota.

"Being in the shadow of the largest medical center on the planet — 106,000 employees show up there every 24 hours," Cohn says, "if you want to innovate, this is the place to do it."

From Your Site Articles
Revisiting a conversation with Dr. Joseph Rogers, president and CEO of the Texas Heart Institute, on the Houston Innovators Podcast. Photo via texasheart.org

Play it back: How this Houstonian is leading heart health innovation

HOUSTON INNOVATORS PODCAST EPISODE 246

Heart health innovation is at a major moment in history — and Houston is at the center of it.

Last summer, Dr. Joseph Rogers, president and CEO of the Houston-based Texas Heart Institute, joined the Houston Innovators Podcast to share how he came to be at the helm of THI, as well as the incredible technologies the institute is working on to address heart failure, a global epidemic affecting at least 26 million people worldwide, 6.2 million adults in the U.S.

This month, one of THI’s technologies reached a major milestone. BiVACOR, a Houston company successfully implanted the company's first Total Artificial Heart in a human. The device was implanted in the patient on July 9. Eight days later, a donor heart became available and was transplanted into the patient, removing the TAH, establishing the device as a successful bridge-to-heart-transplant solution for patients, THI reported.

In addition to this breakthrough in health tech, THI is focused on addressing Cardiometabolic Syndrome at a new conference on Friday, August 23, in Houston. The full-day symposium will take place in collaboration with Arianna Huffington, the founder and CEO of Thrive Global. Dr. Rogers is co-directing the program with Dr. Stephanie Coulter, medical director for THI Center for Women’s Heart & Vascular Health.


In the episode, Rogers explains why he's bullish on Houston and THI leading heart health innovation alongside other health care organizations — nonprofits, universities, local government — to collaborate in ways never been done before. And THI is dedicated to this mission.

"We should act as a convener," Rogers says. "Houston is the place to do this.

"The reason I think this is such an important community to address this problem is it's the most diverse city in the United States. And I've never lived anywhere or heard of another city that I was so convinced believed they could do anything they set their minds to. It's about making the community aware of the problem and a potential solution — and then working on trying to solve it," he continues. "But I think all of the pieces are here to show the world how to do this at a community level."

Emerson Perin of the Texas Heart Institute, recently published the largest clinical trial of cell therapy for patients with chronic heart failure to-date included 580 patients at 52 sites throughout North America. Photo via texasheart.org

Houston health care leader on a mission to innovate an end to heart failure

cardiology cured

Emerson Perin’s end goal isn’t to treat heart failure. The medical director of The Texas Heart Institute says that he has his sights set firmly on curing the malady altogether. And, with the power of innovation and a strong team, the Houston-based cardiologist has a good chance of meeting his objective.

Perin first came to THI for fellowship training in 1988, following his residency in Miami and medical school in his birthplace of Brazil.

“This is a very special place,” the physician and researcher, whose titles also include director for THI’s Center for Clinical Research and vice president for medical affairs, tells InnovationMap. “It has a worldwide-reaching reputation. I’ve always liked research and this is a great place in terms of innovation and practicing high-level cardiology.”

For decades, Perin has followed in THI founder Denton Cooley’s footsteps with world-changing research. In 2001, the founding medical director of THI’s Stem Cell Center was the first person to inject stem cells into a failing human heart. It led to a trial of 17 patients that year.

“A couple of the patients did remarkably well — more than you could ever expect. These guys who couldn’t’ walk across the room pretty much were jogging on the beach. That gave me the initial insight that this works,” Perin recalls.

What exactly is heart failure? The term refers to the condition of a heart that can’t pump enough blood to sustainably power the body through oxygenation of the tissues from blood flow. It may sound like a death sentence, but with appropriate care, it can usually be managed with medicines and if worsening occurs, devices and, ultimately, heart transplantation.

And Perin is proving that there’s a lot of life ahead for heart failure patients. Earlier this year, he published another groundbreaking clinical trial, DREAM-HF. The largest clinical trial of cell therapy for patients with chronic heart failure to-date included 580 patients at 52 sites throughout North America.

With the goal of getting a new cell therapy approved for heart failure, the primary endpoint was to prove that the therapy could prevent recurrent hospitalizations.

“It was a total negative,” says Perin. That’s because the cells don’t have a decongestant effect such as the medicines currently used to treat heart failure.

But that doesn’t mean that the trial was a failure. Quite the opposite. That’s because Perin and his team proved something else: The trial was able to prove that there was significant improvement in patients with inflammation. After those patients were injected with mesenchymal precursor cells (MPC), they showed a 70-percent reduction in heart attacks and strokes. Cardiovascular deaths also decreased.

These are blockbuster numbers, and big news for patients dealing with heart failure. What it means is that the cells addressed a different aspect of heart failure that until now had been left untreated which was the inflammation — how heart failure starts and what keeps it going.

So what’s next? Going to the FDA.

“They said, ‘We can’t approve it with one trial, but we’ll approve it with two,’” says Perin.

This time, his primary endpoint will be tailored to suit the positive outcome he knows he’ll be able achieve. This next round will begin in 2024.

Once the FDA approves a new catheter system for injecting the heart with stem cells and genes, the team will proceed with new studies. Gene therapy will be another frontier for Perin — and patients with heart failure.

“I think the combination of cells and genes is even more powerful,” he says. “That will help save lives in a completely new way and do away with heart failure.”

Perin's work is just one piece of the puzzle, and Dr. Joseph Rogers, who was appointed president and CEO of THI in 2021, is leading the organization's initiative in several ways. THI, recently buoyed by a $32 million donation from a patient — the largest charitable donation in its history — is exploring several innovative therapeutics, devices, and treatments.

THI recently received a two-year, $1.14 million grant from The National Heart, Lung, and Blood Institute to develop a novel, first-in-class drug to treat the cardiovascular disease that arises from atherosclerosis. Another THI innovator, Camila Hochman-Mendez — along with her research team — is studying the effects of regenerative medicine on hearts.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston VC funding surged in Q1 2025 to highest level in years, report says

by the numbers

First-quarter funding for Houston-area startups just hit its highest level since 2022, according to the latest PitchBook-NVCA Venture Monitor. But fundraising in subsequent quarters might not be as robust thanks to ongoing economic turmoil, the report warns.

In the first quarter of 2025, Houston-area startups raised $544.2 million in venture capital from investors, PitchBook-NVCA data shows. That compares with $263.5 million in Q1 2024 and $344.5 million in Q1 2023. For the first quarter of 2022, local startups nabbed $745.5 million in venture capital.

The Houston-area total for first-quarter VC funding this year fell well short of the sum for the Austin area (more than $3.3 billion) and Dallas-Fort Worth ($696.8 million), according to PitchBook-NVCA data.

While first-quarter 2025 funding for Houston-area startups got a boost, the number of VC deals declined versus the first quarters of 2024, 2023 and 2022. The PitchBook-NVCA Monitor reported 37 local VC deals in this year’s first quarter, compared with 45 during the same period in 2024, 53 in 2023, and 57 in 2022.

The PitchBook-NVCA report indicates fundraising figures for the Houston area, the Austin area, Dallas-Fort Worth and other markets might shrink in upcoming quarters.

“Should the latest iteration of tariffs stand, we expect significant pressure on fundraising and dealmaking in the near term as investors sit on the sidelines and wait for signs of market stabilization,” the report says.

Due to new trade tariffs and policy shifts, the chances of an upcoming rebound in the VC market have likely faded, says Nizar Tarhuni, executive vice president of research and market intelligence at PitchBook.

“These impacts amplify economic uncertainty and could further disrupt the private markets by complicating investment decisions, supply chains, exit windows, and portfolio strategies,” Tarhuni says. “While this may eventually lead to new domestic investment and create opportunities, the overall environment is facing volatility, hesitation, and structural change.”

Expert: Texas is building a cybersecurity wall — but it needs more bricklayers

Guest Column

Texas has always been a state that thinks in terms of scale. Big energy, big ambitions and now, big action in cybersecurity.

With the creation of the Texas Cyber Command under the Department of Information Resources, the state is recognizing what many of us in the industry have long understood: cybersecurity is not just an IT issue, it's a matter of public safety and economic resilience. Protecting municipal systems, schools, and critical energy infrastructure from cyber threats is no longer optional. It is essential.

For these efforts to succeed, Texas must invest as much in people as it does in technology. Without a capable, well-trained workforce to carry out the mission, even the strongest cyber strategies will struggle to hold the line.

The scope of the threat

Cyberattacks are not theoretical. In the last year alone, several cities in Texas experienced major ransomware attacks. One incident in Fort Worth took down core city systems, affecting everything from email access to permitting operations. The ripple effects were significant.

The energy sector is also under constant pressure. As a cornerstone of both the Texas and national economy, the it is a high-value target. Hackers are probing systems that manage oil, gas, and renewable energy infrastructure, looking for weaknesses that could be exploited to steal data or disrupt operations.

Texas has responded by centralizing its cyber incident response capabilities. The Texas Cyber Command is a smart step forward. It brings coordination and focus to an increasingly complex landscape. But its effectiveness will depend entirely on the professionals tasked with doing the work. And that’s where the challenge lies.

The workforce gap

Across the U.S., there are an estimated 400,000 unfilled cybersecurity positions. In Texas, more than 40,000 roles remain vacant, according to CyberSeek. These are not just numbers in a report. They represent a growing vulnerability with gaps in frontline defenses against real and persistent threats.

We cannot afford to rely solely on traditional pathways to fill this gap. Four-year degree programs are important, but they are not designed to scale fast enough or flexibly enough to meet today’s needs. Instead, we need to broaden our view of what a cybersecurity talent pipeline looks like and who it includes.

There needs to be an expanded focus on practical, skills-based training that takes high-aptitude individuals, including those from non-traditional backgrounds, and prepares them for success in cybersecurity careers through rigorous hands-on training that reflects the demands of real-world cyber roles. With the right structure and support, people from all walks of life are already proving they can become capable defenders of our digital infrastructure.

The same entrepreneurial spirit that drives innovation in other sectors can be applied to cybersecurity workforce development. We don’t have to wait years to grow the next generation of defenders. We can do it now, with the right focus and investment.

Texas has taken a critical first step by creating the Cyber Command, but if we want to build lasting resilience, we need to address the workforce bottleneck head-on. Cybersecurity needs more than tech…it needs talent.

---

Dean Gefen is theCEO, NukuDo, a San Antonio-based cybersecurity workforce development and staffing company.

Rice Business Plan Competition doles out $2M to 2025 student teams

big winners

Celebrating its 25th year, the Rice Alliance for Technology and Entrepreneurship hosted the celebrated Rice Business Plan Competition this month, doling out more than $2 million in investment and cash prizes to the top-performing teams.

“For 25 years, the Rice Business Plan Competition has helped shape how Rice Business shows up in the world by creating a platform where student-entrepreneurs can tackle some of the most complex challenges of our time in energy, in health care, in technology and beyond,” Peter Rodriguez, dean of Rice Business, the presenting sponsor of the event, said in a news release. “If we’re serious about changing the world — and I believe we are — then it’s our responsibility to open doors for students everywhere to imagine bold solutions and build what comes next.”

Over the course of the three-day event, the 42 startups competing this year from colleges or universities around the world presented their plans before more than 300 angel, venture capital, and corporate investors. The teams were selected from the event’s largest applicant pool to date and represented 34 universities across four countries, according to Rice. Winners were announced at the company showcase and awards ceremony April 12 in downtown Houston.

Seven finalists were selected, though each team left the competition with some form of funding, according to Rice. The University of Michigan's Intero Biosystems was the star of the show, bringing home both the top-place finish and the largest total investment. Rice's own Pattern Materials also had a strong showing, placing fourth in the pitch competition and also earning the fourth-highest investment total.

Here are the teams that won big in 2025. See a full list of winners and prizes here.

Intero Biosystems, University of Michigan - $902,000

The team finished in first place for its GastroScreen, the first stem cell-driven human “mini gut” that is ideal for organ function testing before testing on humans, and also claimed the largest total investments among the competition.

  • $150,000 Goose Capital Investment Grand Prize
  • $250,000 Goose Capital Investment Prize
  • $200,000 The OWL Investment Prize
  • $100,000 Houston Angel Network Investment Prize
  • $100,000 nCourage Investment Network’s Courageous Women Entrepreneur Investment Prize
  • $100,000 Investment Prize from Nancy Chang
  • $1,000 Mercury Elevator Pitch Competition - Overall Winner
  • $1,000 Anbarci Family Company Showcase Prize
  • TMC Innovation Healthcare Accelerator Bootcamp Invitation Prize

MabLab, Harvard University – $301,500

The team placed second for its rapid test capable of detecting multiple adulterants in laced drugs and spiked drinks.

  • $100,000 Investment Prize, sponsored by David Anderson, Anderson Family Fund, Jon Finger and Finger Interests
  • $100,000 The Indus Entrepreneurs (TiE) Texas Angels Investment Prize
  • $25,000 nCourage Investment Network’s Courageous Women Entrepreneur Investment Prize
  • $50,000 Valhalla Investment Network Investment Prize
  • $25,000 The Eagles Investor Investment Prize
  • $500 Mercury Elevator Pitch Competition - Life Science*
  • $1,000 Anbarci Family Company Showcase Prize

re.solution, RWTH Aachen University — $76,500

The team placed third for its water-based technology that recycles polyesters without generating salt waste, making textile recycling viable.

  • $50,000 Investment Prize, sponsored by David Anderson, Anderson Family Fund, Jon Finger and Finger Interests
  • $25,000 Pearland EDC Spirit of Entrepreneurship Cash Prize
  • $500 Mercury Elevator Pitch Competition - Energy/Cleantech
  • $1,000 Anbarci Family Company Showcase Prize

Pattern Materials, Rice University – $134,500

The Houston-based team placed fourth for its laser-induced graphene technology that can be rapidly performed, enabling low-cost, scalable production of the material.

  • $5,000 prize, sponsored by Norton Rose Fulbright
  • $50,000 Valhalla Investment Network Investment Prize
  • $25,000 Pearland EDC Spirit of Entrepreneurship Cash Prize
  • $25,000 New Climate Ventures Sustainable Investment Prize
  • $25,000 Amentum and WRX Companies Rising Stars Space Technology and Commercial Aerospace Cash Prize
  • $500 Mercury Elevator Pitch Competition - Hard Tech
  • $1,000 Anbarci Family Company Showcase Prize
  • $3,000 Venture Builder Innovation Prizes

Xatoms, Western University and University of Toronto — $30,000

The team placed fifth for its AI- and quantum-driven platform for discovering solar-activated semiconductor materials.

  • $5,000 prize, sponsored by EY
  • $25,000 nCourage Investment Network’s Courageous Women Entrepreneur Investment Prize

Mito Robotics, Carnegie Mellon University— $5,000

The team placed sixth for its automated manual cell culture with AI-powered robotic scientists for life science research

  • $5,000 prize, sponsored by Chevron Technology Ventures

FarmSmart.ai, LSU – $106,000

The team placed seventh for its AI—driven assistant that synthesizes vast agricultural research into actionable, tailored intelligence, but earned the fifth-most investments among the group.

  • $5,000 prize, sponsored by Shell Ventures
  • $100,000 The OWL Investment Prize
  • $1,000 Anbarci Family Company Showcase Prize
  • Edward H. Molter Memorial Prizes for Wildcard Round - 1st place - Advance to Finals


Other significant awards

GreenLIB Materials, University of Ottawa – $152,000

  • $150,000 Goose Capital Investment Prize
  • $2,000 Venture Builder Innovation Prizes

Microvitality, Tufts University – $26,500

  • $25,000 Southwest National Pediatric Device Consortium Pediatric Device Cash Prize
  • $1,500 Edward H. Molter Memorial Prizes for Wildcard Round - 3rd place overall in WC

Nanoborne, University of Texas at Austin - $25,000

  • $25,000 NOV Golden Ticket to Supernova Accelerator and Cash Prize

Last year, the Rice Business Plan Competition facilitated over $1.5 million in investment and cash prizes. MesaQuantum from Harvard University landed the highest total investment last year, although it was not named a finalist. Protein Pints from Michigan State University won the pitch competition.

According to Rice, 910 startups have raised more than $6.9 billion in capital through the competition over the last 25 years.

View All Listings